TMBR...$2.44...in the P/M...Basking Ridge, NJ - (NewMediaWire) - March 17, 2021 - Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its development partner, AFT Pharmaceuticals Limited ("AFT"), has signed an exclusive license and supply agreement with Desitin Arzneimittel GmbH ("Desitin") for Pascomer(R) (TMB-002 topical rapamycin) for the treatment of facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC) in Europe.
Realized Gains = Certainty...Unrealized Gains = Meaningless...
